Abbvie Inc (ABBV)

$253.35 +10.21 (4.20%)
Market Cap 447.62B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.86
Forward PE 17.03
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 52,635,000
Avg Vol 7,227,618
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 100%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 3:42 PM
$SLS $ABBV Does Every One know - Aza+VEN, BAT - Best Available Treatment for SLS P3 Control Arm Patients Recently Failed 4 large AML Trials conducted by ABBV? - Including FAILING 3 For AML Remission Maintenance? VIALE-M Phase 3 Trial for CR1 Maintenance FAILED VIALE-T Phase 3 Trial For post Transplant Maintenance Failed Large Phase 2 Reduced Intensity all Oral Failed Verona Phase 3 HR MDS/AML Precursor Failed -- AND -- We have 3 Dr's treating Actual SLS Phase 3 Patients on the Record Stating BAT is Toxic, MOS is 'Not Durable', 'Extremely poor", 'just 6-8 months 5-7 months' ---AND " I strongly believe Gps will reach the primary Endpoint "... It is not Complicated.
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:59 PM
$ABBV MUCH LOVE❤️
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:57 PM
$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 🤑 667% GAINER! ☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 29 at 2:56 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 667% GAINER!
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:35 PM
Telegram channel: https://t.me/BlockWave10 $ABBV You can call me the GOAT if you want. 😂🫶🏻 Heaven knows I’ll keep doing my part. Keep missing these opportunities, and you’ll keep missing out on making some serious profit.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM
$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM
$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 29 at 2:06 PM
$ABBV Take a look🥂
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:01 PM
$ABBV $PFE $RVMD $SLS 🤩 Over 6.4 million Volume in first half hour up over 15%. I expect a T 1 halt before the Biggest Catalyst in Sellas Corporate history GPS Regal Pivotal Registrational phase 3 data= $120.00+ BO= $240.00+ Bidding War= $280.00+ ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 1:49 PM
$ABBV $PFE $RVMD $SLS Potential T1 halt before next Catalyst. Traders and Repositioners will be left on the sidelines! SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹
0 · Reply
Latest News on ABBV
AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

2026-06-29T09:20:22.000Z - 6 hours ago

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 9 hours ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 9 hours ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

2026-06-26T20:55:10.000Z - 2 days ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 2 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 3 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 4 days ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 5 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:54:44.000Z - 6 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

2026-06-23T12:22:00.000Z - 6 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 6 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 6 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 6 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 6 days ago

AbbVie announces European Commission approval for Skyrizi

AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 6 days ago

AbbVie announces European Commission approval of Maviret

AbbVie announces EU approval of Skyrizi for pediatric patients

2026-06-23T09:46:03.000Z - 6 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 6 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 6 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

2026-06-22T21:55:09.000Z - 6 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 7 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Press release: M&A announcement

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

2026-06-22T12:24:03.000Z - 7 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 7 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

2026-06-22T11:10:51.000Z - 7 days ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 7 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 7 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 7 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

2026-06-22T10:48:07.000Z - 7 days ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 9 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 10 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 10 days ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 13 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 17 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 18 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 19 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 20 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 21 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 25 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 26 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 27 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 3:42 PM
$SLS $ABBV Does Every One know - Aza+VEN, BAT - Best Available Treatment for SLS P3 Control Arm Patients Recently Failed 4 large AML Trials conducted by ABBV? - Including FAILING 3 For AML Remission Maintenance? VIALE-M Phase 3 Trial for CR1 Maintenance FAILED VIALE-T Phase 3 Trial For post Transplant Maintenance Failed Large Phase 2 Reduced Intensity all Oral Failed Verona Phase 3 HR MDS/AML Precursor Failed -- AND -- We have 3 Dr's treating Actual SLS Phase 3 Patients on the Record Stating BAT is Toxic, MOS is 'Not Durable', 'Extremely poor", 'just 6-8 months 5-7 months' ---AND " I strongly believe Gps will reach the primary Endpoint "... It is not Complicated.
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:59 PM
$ABBV MUCH LOVE❤️
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:57 PM
$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 🤑 667% GAINER! ☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 29 at 2:56 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 667% GAINER!
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:35 PM
Telegram channel: https://t.me/BlockWave10 $ABBV You can call me the GOAT if you want. 😂🫶🏻 Heaven knows I’ll keep doing my part. Keep missing these opportunities, and you’ll keep missing out on making some serious profit.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM
$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM
$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 29 at 2:06 PM
$ABBV Take a look🥂
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:01 PM
$ABBV $PFE $RVMD $SLS 🤩 Over 6.4 million Volume in first half hour up over 15%. I expect a T 1 halt before the Biggest Catalyst in Sellas Corporate history GPS Regal Pivotal Registrational phase 3 data= $120.00+ BO= $240.00+ Bidding War= $280.00+ ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 1:49 PM
$ABBV $PFE $RVMD $SLS Potential T1 halt before next Catalyst. Traders and Repositioners will be left on the sidelines! SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 29 at 1:40 PM
OH MY GOD!!!!!! I JUST MADE $19,000+ ON $ABBV I DO NOT MISS (NFA)
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 1:37 PM
I JUST MADE $19,000+ ON $ABBV I DO NOT MISS ON MY HIGH CONFIDENCES!!!!!!
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 29 at 1:36 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $2.50 481% GAINER!
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 29 at 1:36 PM
$1.00 on $ABBV here! 47% return!
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 29 at 1:36 PM
$ABBV 🩺 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $2.50 🤑 481% GAINER! ☢️☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️ (NFA)
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 1:34 PM
$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $2.50 🤑 481% GAINER! ☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️
0 · Reply
ZacksResearch
ZacksResearch Jun. 29 at 1:31 PM
"Biotech is on fire 🔥 But which names are driving the rally? $LLY, $ABBV, $JNJ and $BIIB all hit fresh 52-week highs as strong pipeline progress, regulatory wins, approvals and M&A activity fueled growing confidence across the biotech sector. 📈 Latest LLY news here👉 " https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-38568&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38568
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 1:20 PM
$ABBV $PFE $RVMD $SLS 3 trading day left going in to the 4Th of July holiday shortened weekend. July 3Rd Stock market is closed. 63 Million short trap with 0 shares to Borrow going in to a 3 day holiday weekend awaiting the biggest Catalyst in Sellas Corporate history GPS Regal Pivotal Registrational phase 3 Top line data = $120.00+ BO= $240.00+ Bidding War= $280.00+ ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 1:10 PM
$ABBV $PFE $RVMD $SLS My Long Brothers and Sisters here at Sellas 1 more trading day left till July 2026. $RVMD added $5 Billion for every month life extended for one ☝️ of the deadliest cancer on the planet $SLS is on the cusp of a CURATIVE cancer platform for the deadliest cancers on the planet 👇 and SLS MC is below $3 Billion. What a travesty? SLS MC should be over $5 Billion right given the potential of Curative outcome for 20+ WT1 cancers. 👇 ✌️🙏❤️‍🩹
0 · Reply
TaylorEquityGroup
TaylorEquityGroup Jun. 29 at 12:45 PM
$ABBV $LLY $UNH Helathcare sector leading currently, SPY needs a catalyst to keep the rally going $SPY
1 · Reply
KryptonResearch
KryptonResearch Jun. 29 at 12:37 PM
While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 12:17 PM
$SLS $PFE $ABBV $BMY $MRK Bidding war is here now. 3 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. GPS REGAL Pivotal Registrational phase 3 data is about to deliver a CURATIVE oncology Platform and all my Long Brothers and Sisters you are about to witness the most consequential and contested acquisition seen in a generation. 🙏✌️❤️‍🩹
0 · Reply